相关实验视频

Updated: Sep 17, 2025

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

开发和体外优化telmisartan-curcumin固体分散纳米颗粒用于使用doe方法管理糖尿病病

Aruna Rawat¹, Samrat Chauhan², Rahul Pratap Singh¹

¹Department of Pharmaceutical Science, School of Healthcare and Allied Science, GD Goenka University, Gurugram, Haryana, India.

Drug development and industrial pharmacy

|July 2, 2025

概括

这项研究开发了Telmisartan-Curcumin固体分散纳米颗粒 (SDN) 来增强Telmisartan溶解性和释放糖尿病病. 优化的配方显示改善了药物输送,黄素显著提高了治疗潜力.

科学领域:

制药科学制药科学
纳米技术纳米技术
药物输送系统药物输送系统

背景情况:

糖尿病病 (DN) 是糖尿病的一个主要并发症,导致损伤.
泰尔米沙坦是一种血管激素II受体抑制剂,用于治疗高血压和DN,但其溶解性差限制了疗效.
开发新型药物输送系统对于提高Telmisartan在DN管理中的治疗潜力至关重要.

研究的目的:

开发和优化Telmisartan-Curcumin固体分散纳米颗粒 (SDNs). 为了开发和优化Telmisartan-Curcumin固体分散纳米颗粒.
提高泰尔米沙坦的溶解性和释放率,以改善糖尿病病管理.
评估黄素在改善特尔米沙坦配方治疗疗效方面的作用.

主要方法:

使用Box-Behnken设计优化Telmisartan-Curcumin SDNs,使用PVP VA S630和Poloxamer 407.7进行设计.
对特尔米萨坦的溶解性和脂性进行了制剂前研究.
通过使用TEM成像来评估可溶性,颗粒大小,泽塔潜力和体外药物释放动力学的优化配方 (TLS-15).

主要成果:

优化的特尔米沙坦-库尔库明SDN (TLS-15) 显示出显著增强的溶解度 (4.801μg/ml) 和药物释放率 (99.68%).
TLS-15显示了最佳粒子大小 (303.5 nm) 和泽塔电位 (-12.17 mV),表明了良好的纳米粒子稳定性.
TEM证实均分布的球形纳米粒子,释放动力学跟随第一阶释放 (R2 = 0.9934),在6小时内释放99.54%.

结论:

成功开发和优化了Telmisartan-Curcumin SDNs,显著改善了Telmisartan的溶解性和释放特征.
黄素的结合极大地提高了特尔米沙坦在糖尿病病治疗中的治疗潜力和生物可用性.
虽然制造和稳定性需要进一步研究,但该配方对有效的糖尿病病治疗有希望.

关键词:

提高生物可用性提高生物可用性盒子背面的设计设计库尔库明是一种黄素.糖尿病脏病 - 糖尿病脏病在QbD中,它是QbD.固体分散纳米粒子固体分散纳米粒子泰尔米沙坦 (telmisartan) 是一种药物.

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Published on: July 30, 2020

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...